Reported 10 days ago
Cassava Sciences (SAVA) has agreed to pay a $40 million fine to the U.S. Securities and Exchange Commission (SEC) following charges of making misleading claims regarding an Alzheimer's clinical trial. The company's shares have seen a decline in response to the settlement.
Source: YAHOO